Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Jiuyuan Gene Engineering Files for China Approval of Ozempic Biosimilar

publication date: Apr 8, 2024

Hangzhou Jiuyuan Gene Engineering, along with its major shareholder, Huadong Medicine, has filed for approval of Jiyoutai, its biosimilar to Novo Nordisk’s Ozempic (semaglutide), a weight loss drug. Novo Nordisk holds patent rights to the drug in China until 2026. Ozempic was the world's best-selling diabetes drug last year, even though most of the sales came from people using the drug to lose weight. The active ingredient of the drug, semaglutide, is also used at a lower dose in Novo’s Wegovy, which targets weight loss. Jiyoutai could become the first approved China developed semaglutide biosimilar. More details....

Share this with colleagues:  



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital